Kelsey R. Monson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kelsey R. Monson has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Tomas Kirchhoff
Perlmutter Cancer Center, New York University School of Medicine, New York, NY, United States
20 shared publications - Iman Osman
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA
18 shared publications - Leah Morales
Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York. 1
18 shared publications - Anabelle Bunis
Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York. 1
17 shared publications - Brandilyn A. Peters
Department of Epidemiology and Population Health, Albert Einstein College of Medicine
17 shared publications - Caroline Y. Um
Department of Population Science, American Cancer Society , Atlanta, GA
17 shared publications
Latest Publications
- 10 November 2026
- Published by Springer Nature in Nature Medicine
- p. 1-2
A novel candidate biomarker for detecting premalignant and early ovarian cancer
- 10 November 2026
- Published by Springer Nature in Nature Medicine
- p. 1-2
A novel candidate biomarker for detecting premalignant and early ovarian cancer
- Open Access
- 5 June 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (7) , 2385-2396
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma
Response to immune checkpoint inhibitors (ICIs) in metastatic melanoma (MM) varies among patients, and current baseline biomarkers predicting treatment outcomes are limited. As mitochondrial (MT) metabolism has emerged as an important regulator of host immune function, we explored the association of host MT genetics (MT haplogroups) with ICI efficacy in 1,225 ICI-treated patients with MM from the clinical trial CheckMate-067 and the International Germline Immuno-Oncology Melanoma Consortium. We discovered and validated significant associations of MT haplogroup T (HG-T) with resistance to anti-programmed cell death protein-1-based ICI (both single-agent and combination) and have shown that HG-T is independent from established tumor predictors. We also found that patients belonging to HG-T exhibit a unique nivolumab-resistant baseline peripheral CD8+ T cell repertoire compared to other MT haplogroups, providing, to our knowledge, the first link between MT inheritance, host immunity and ICI resistance. The study proposes a host blood-based biomarker with stand-alone clinical value predicting ICI efficacy and points to an ICI-resistance mechanism associated with MT metabolism, with clinical relevance in immuno-oncology.
- 5 June 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (7) , 2385-2396
Open AccessInherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma
Response to immune checkpoint inhibitors (ICIs) in metastatic melanoma (MM) varies among patients, and current baseline biomarkers predicting treatment outcomes are limited. As mitochondrial (MT) metabolism has emerged as an important regulator of host immune function, we explored the association of host MT genetics (MT haplogroups) with ICI efficacy in 1,225 ICI-treated patients with MM from the clinical trial CheckMate-067 and the International Germline Immuno-Oncology Melanoma Consortium. We discovered and validated significant associations of MT haplogroup T (HG-T) with resistance to anti-programmed cell death protein-1-based ICI (both single-agent and combination) and have shown that HG-T is independent from established tumor predictors. We also found that patients belonging to HG-T exhibit a unique nivolumab-resistant baseline peripheral CD8+ T cell repertoire compared to other MT haplogroups, providing, to our knowledge, the first link between MT inheritance, host immunity and ICI resistance. The study proposes a host blood-based biomarker with stand-alone clinical value predicting ICI efficacy and points to an ICI-resistance mechanism associated with MT metabolism, with clinical relevance in immuno-oncology.
- Open Access
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Data from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma
Purpose:Immune checkpoint inhibition (ICI) shows benefits in adjuvant (AT) and neoadjuvant melanoma treatments. However, ICI frequently induces severe immune-related adverse events (irAE). Unlike metastatic disease, in which irAEs are a clinical trade-off for treatment that improves survival, the toxicity burden from ICI in the AT setting is a substantial clinical problem urging for irAE-predictive biomarkers.Experimental Design:We assessed postsurgical, pre–ICI treatment peripheral CD4+ and CD8+ T cells from clinical trial patients (CheckMate 915) treated with AT nivolumab (n = 130) or ipilimumab/nivolumab (COMBO, n = 82). Performing RNA sequencing differential gene expression analysis, we tested baseline differences associated with severe (grades 3–5) irAEs and constructed an irAE-predictive model using least absolute shrinkage and selection operator–regularized logistic regression.Results:The analysis of predicted protein–protein interactions among differentially expressed genes in peripheral CD4+ cells revealed significant enrichment of the spleen tyrosine kinase (SYK) pathway, associated with severe irAEs in COMBO-treated patients. This gene expression signature predicted severe-irAE COMBO patients (χ2P value = 0.001) with 73% accuracy and was independent of disease recurrence (P = 0.79). The irAE-predictive model incorporating this gene expression signature demonstrated 82% accuracy (χ2P value = 8.91E−06).Conclusions:We identified baseline gene expression differences in key immune pathways of peripheral blood T cells from COMBO-treated patients with grades 3 to 5 irAEs and defined a SYK-related gene signature correctly identifying ∼60% of COMBO-treated patients with grades 3 to 5 irAEs. This finding aligns with our previous work linking anti-CTLA4 irAEs with a germline variant associated with high SYK expression. This gene signature may serve as a baseline biomarker of severe grade 3 to 5 irAE risk, which is especially important in AT treatment.
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma
Purpose:Immune checkpoint inhibition (ICI) shows benefits in adjuvant (AT) and neoadjuvant melanoma treatments. However, ICI frequently induces severe immune-related adverse events (irAE). Unlike metastatic disease, in which irAEs are a clinical trade-off for treatment that improves survival, the toxicity burden from ICI in the AT setting is a substantial clinical problem urging for irAE-predictive biomarkers.Experimental Design:We assessed postsurgical, pre–ICI treatment peripheral CD4+ and CD8+ T cells from clinical trial patients (CheckMate 915) treated with AT nivolumab (n = 130) or ipilimumab/nivolumab (COMBO, n = 82). Performing RNA sequencing differential gene expression analysis, we tested baseline differences associated with severe (grades 3–5) irAEs and constructed an irAE-predictive model using least absolute shrinkage and selection operator–regularized logistic regression.Results:The analysis of predicted protein–protein interactions among differentially expressed genes in peripheral CD4+ cells revealed significant enrichment of the spleen tyrosine kinase (SYK) pathway, associated with severe irAEs in COMBO-treated patients. This gene expression signature predicted severe-irAE COMBO patients (χ2P value = 0.001) with 73% accuracy and was independent of disease recurrence (P = 0.79). The irAE-predictive model incorporating this gene expression signature demonstrated 82% accuracy (χ2P value = 8.91E−06).Conclusions:We identified baseline gene expression differences in key immune pathways of peripheral blood T cells from COMBO-treated patients with grades 3 to 5 irAEs and defined a SYK-related gene signature correctly identifying ∼60% of COMBO-treated patients with grades 3 to 5 irAEs. This finding aligns with our previous work linking anti-CTLA4 irAEs with a germline variant associated with high SYK expression. This gene signature may serve as a baseline biomarker of severe grade 3 to 5 irAE risk, which is especially important in AT treatment.
- Open Access
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma
Supplementary Figure S6. Correlation plots for predictor variables in cross-validation logistic regression models.
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma
Supplementary Figure S6. Correlation plots for predictor variables in cross-validation logistic regression models.
- Open Access
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma
Supplementary Table S8. Confusion matrix for top LASSO-regularized and cross-validated logistic regression model predicting severe (grade 3-4) irAEs (age, stage, and CD22, PAG1, CD33, HNRNPU, and FCGR2C gene expression) in COMBO-treated patients.
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma
Supplementary Table S8. Confusion matrix for top LASSO-regularized and cross-validated logistic regression model predicting severe (grade 3-4) irAEs (age, stage, and CD22, PAG1, CD33, HNRNPU, and FCGR2C gene expression) in COMBO-treated patients.
- Open Access
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma
Supplementary Table S1. irAE event and grades for the patient population.
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma
Supplementary Table S1. irAE event and grades for the patient population.
- Open Access
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma
Supplementary Table S4: Predicted PPI for differentially expressed genes identified in the study.
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma
Supplementary Table S4: Predicted PPI for differentially expressed genes identified in the study.
- Open Access
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma
Supplementary Figure S7. Waterfall plot for logistic regression model predicting severe (grade 3-5) irAEs using 24-gene SYK GEP.
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma
Supplementary Figure S7. Waterfall plot for logistic regression model predicting severe (grade 3-5) irAEs using 24-gene SYK GEP.
- Open Access
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma
Supplementary Table S5. Gene signature for COMBO CD4+ DEGs in MAPK8 and MAPK14 pathways, High vs Low Toxicity.
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma
Supplementary Table S5. Gene signature for COMBO CD4+ DEGs in MAPK8 and MAPK14 pathways, High vs Low Toxicity.
- Open Access
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma
Supplementary Table S3. GO analysis of differentially expressed genes identified in the study.
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma
Supplementary Table S3. GO analysis of differentially expressed genes identified in the study.